Literature DB >> 19289422

The role of radiotracer imaging in the diagnosis and management of patients with breast cancer: part 1--overview, detection, and staging.

Jean H Lee1, Eric L Rosen, David A Mankoff.   

Abstract

Breast cancer is the most common non-skin type of cancer and the second leading cause of cancer mortality in women. Advances in diagnosis and treatment have led to declines in mortality, despite an increase in breast cancer incidence. An advancing array of both local and systemic therapy options has led to increasingly individualized treatment. Imaging plays a key role in detecting breast cancer and directing its therapy. This continuing education article, part 1 in a 2-part series, provides a comprehensive review of current and future radiotracer imaging methods applied to breast cancer, in the context of breast cancer management strategies and other nonnuclear imaging methods. Part 1 of the review provides an overview of clinical and biologic considerations in breast cancer and covers radionuclide imaging for detection and staging. Part 2 will cover radionuclide imaging of breast cancer response to therapy, other clinical indications for radionuclide breast cancer imaging, and future directions, including molecular imaging.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19289422     DOI: 10.2967/jnumed.108.053512

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  8 in total

Review 1.  Development of radiotracers for oncology--the interface with pharmacology.

Authors:  Rohini Sharma; Eric Aboagye
Journal:  Br J Pharmacol       Date:  2011-08       Impact factor: 8.739

Review 2.  Use of Diagnostic Imaging Modalities in Modern Screening, Diagnostics and Management of Breast Tumours 1st Central-Eastern European Professional Consensus Statement on Breast Cancer.

Authors:  Gábor Forrai; Eszter Kovács; Éva Ambrózay; Miklós Barta; Katalin Borbély; Zsolt Lengyel; Katalin Ormándi; Zoltán Péntek; Tasnádi Tünde; Éva Sebő
Journal:  Pathol Oncol Res       Date:  2022-06-08       Impact factor: 2.874

3.  (18)F-FDG PET/CT predicts survival in patients with inflammatory breast cancer undergoing neoadjuvant chemotherapy.

Authors:  Selin Carkaci; Christopher T Sherman; Efe Ozkan; Beatriz E Adrada; Wei Wei; Eric M Rohren; Osama R Mawlawi; Naoto T Ueno; Thomas A Buchholz; Wei T Yang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-07-23       Impact factor: 9.236

4.  A novel ligand delivery system to non-invasively visualize and therapeutically exploit the IL13Rα2 tumor-restricted biomarker.

Authors:  Van Nguyen; Jesse M Conyers; Dongqin Zhu; Denise M Gibo; Roy R Hantgan; Steven M Larson; Waldemar Debinski; Akiva Mintz
Journal:  Neuro Oncol       Date:  2012-09-05       Impact factor: 12.300

5.  Comparative functional evaluation of immunocompetent mouse breast cancer models established from PyMT-tumors using small animal PET with [(18)F]FDG and [(18)F]FLT.

Authors:  Alan Desilva; Melinda Wuest; Monica Wang; Jeff Hummel; Karen Mossman; Frank Wuest; Mary M Hitt
Journal:  Am J Nucl Med Mol Imaging       Date:  2011-12-15

6.  Multiplex photoacoustic molecular imaging using targeted silica-coated gold nanorods.

Authors:  Carolyn L Bayer; Yun-Sheng Chen; Seungsoo Kim; Srivalleesha Mallidi; Konstantin Sokolov; Stanislav Emelianov
Journal:  Biomed Opt Express       Date:  2011-06-02       Impact factor: 3.732

7.  Clinical impact of (18)F-FDG PET/CT on initial staging and therapy planning for breast cancer.

Authors:  Bengul Gunalp; Semra Ince; Alper Ozgur Karacalioglu; Asli Ayan; Ozdes Emer; Engin Alagoz
Journal:  Exp Ther Med       Date:  2012-08-09       Impact factor: 2.447

Review 8.  The role of general nuclear medicine in breast cancer.

Authors:  Lacey R Greene; Deborah Wilkinson
Journal:  J Med Radiat Sci       Date:  2015-02-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.